US stocks fluctuate | Replimune (REPL.US) plunges 76% Skin cancer therapy FDA rejected

According to the Zhitong Finance APP, US regulatory agencies rejected a skin cancer treatment method from Replimune (REPL.US), once again showing that the new leadership of the regulatory agency has taken a tough stance on drug approvals. After the news was announced, as of the time of publication, Replimune's stock price plummeted by 76% at the opening.